Targeting BCL2 pathways in CLL: a story of resistance and ingenuity  

作　　者：Amanda Reyes Tanya Siddiqi 

机构地区：[1]Hematology&Oncology,City of Hope,Duarte,CA 91010,USA [2]Hematology/HCT,City of Hope,Duarte,CA 91010,USA

出　　处：《Cancer Drug Resistance》2023年第4期828-837,共10页癌症耐药（英文）

摘　　要：Chronic lymphocytic leukemia(CLL)is common amongst leukemic malignancies,prompting dedicated investigation throughout the years.Over the last decade,the treatment for CLL has significantly advanced with agents targeting B-cell lymphoma 2(BCL2),Bruton's tyrosine kinase,and CD20.Single agents or combinations of these targets have proven efficacy.Unfortunately,resistance to one or multiple of the new treatment targets develops.Our review investigates various mechanisms of resistance to BCL2 inhibitors,including mutations in BCL2,alterations in the Bcl protein pathway,epigenetic modifications,genetic heterogeneity,Richter transformation,and alterations in oxidative phosphorylation.Additionally,the review will discuss potential avenues to overcome this resistance with novel agents such as bispecific antibodies,Bruton's tyrosine kinase(BTK)degraders,non-covalent BTK inhibitors,and chimeric antigen receptor T(CART).

关 键 词：BCl-2 inhibitors apoptosis CLL RESISTANCE tumor microenvironments cell cycle regulation genetic mutations EPIGENETICS richter transformation 

分 类 号：R733.7[医药卫生—肿瘤]